TOP > 外国特許検索 > CARTILAGE/BONE DESTRUCTION SUPPRESSOR

CARTILAGE/BONE DESTRUCTION SUPPRESSOR 新技術説明会

外国特許コード F130007215
整理番号 S2011-1158-N0
掲載日 2013年3月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP070872
国際公開番号 WO 2013027658
国際出願日 平成24年8月10日(2012.8.10)
国際公開日 平成25年2月28日(2013.2.28)
優先権データ
  • 特願2011-180899 (2011.8.22) JP
発明の名称 (英語) CARTILAGE/BONE DESTRUCTION SUPPRESSOR 新技術説明会
発明の概要(英語) The purpose of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of a cartilage or a bone occurring in rheumatoid arthritis, osteoarthritis, the bone metastasis of a malignant tumor and the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor β or a complex of the antibody and a biologically or chemically active substance.
従来技術、競合技術の概要(英語) BACKGROUND ART
(Osteoarthritis(OA) ) is osteoarthritis, or aging due to mechanical stress, the decay of the surface of the articular cartilage, accompanying proliferation of new cartilage side edges of the joint, joint deformation, compatible in terms of the papermaking machine, and then proceeds to the further joint synovial inflammation is a disease. On the other hand, a typical arthritis in rheumatoid arthritis (rheumatoid arthritis (RA) ) in, and infection due to immune disorder, an inflammatory cells infiltrating the synovial membrane, further, angiogenesis in the synovial membrane with proliferation of the fibroblasts and when increased, inflammatory synovial granulation tissue is formed, destruction of the bone or cartilage proceeds, results in irreversible joint failure. For this reason, inflammatory disease rheumatoid arthritis (RA) whereas the called autoimmune diseases, osteoarthritis (OA) are referred to as a non-inflammatory diseases. Therefore, the therapeutic agent is used in the treatment of rheumatoid arthritis, osteoarthritis in a therapeutic effect is not thought to be general. Conventional, for the purpose of treating rheumatoid arthritis (RA) various pharmaceutical compositions have been developed. As one of the one of the 1 antibody and anti-Fas(patent document 1). However, anti-Fas antibody, rheumatoid arthritis (RA) of the synovial cells obtained from the patient but for apoptosis-inducing effect, of osteoarthritis (OA) synovial cells obtained from the patient to be ineffective for the induction of apoptosis have been reported (non-patent document 1). Current, osteoarthritis and rheumatoid arthritis joint as topical administration of adrenal cortical hormone and hyaluronic acid preparation is used, and the effect is temporary, the effects of these to inflammation and cartilage, constant for findings of the effect of suppressing bone destruction has not been obtained yet (non-patent document 2 and 3). In addition, various biologies (anti-TNF α antibody and the like) in the systemic administration of, cartilage inflammation RA, shown have an effect of suppressing bone destruction, systemic administration can also be treated by the resist (non-patent document 4) have arthritis. These organisms resistant to systemic administration of the formulation RA arthritis, further biological joint cartilage and performing a topical administration, the effect of suppressing bone destruction constant for not obtained findings of the (non-patent document 5). Far from the study of the inventors of the present invention, folate receptor (FR-β) β FR-β expression macrophages immunotoxins is at the center of the pathological condition of a disease or inhibit the inflammation can be easily estimated, administration of adrenal cortical hormone and hyaluronic acid as can be seen, the non-patent reference 6 as also discussed, cartilage is not necessarily an inflammation-suppressing, are not limited to suppress bone destruction. In fact, RA cartilage, bone destruction in an osteoclast differentiated from macrophages, macrophages produce cytokines such as TNF-α or IL-1, produced by macrophages and fibroblasts as a result of the metalloproteases and the like are considered to be complicatedly entangled (non-patent document 7-9). Patent Document 2 is, with respect to the folic acid receptor β toxin IgG-type antibody (Pseudomonas, exotoxin (Pseudomonas exotoxin) ) becomes bound to the synovial cells of rheumatoid arthritis patients to immunotoxins is cell death (apoptosis) induced is described, cartilage, bone destruction suppressing effect is not confirmed, osteoarthritis (OA) has not been discussed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • MATSUYAMA, Takami
  • NAGAI, Taku
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close